Jazz files Xyrem for fibromyalgia in the US
21 December 2009
Katie McQue
Please Login to read the full article.
21 December 2009
Katie McQue
katie.mcque@informa.com
Jazz Pharmaceuticals has filed its fibromyalgia candidate Xyrem (sodium oxybate/JZP-6) with the US FDA.
Fibromyalgia is a chronic condition with symptoms of widespread musculoskeletal pain and fatigue, for which the cause is still unknown.
The filing is based on two Phase III trials....
Please Login to read the full article.
RELATED CONTENT
NEWS
- Tonix reverses into US public shell, raising $1.1 million and questions
- US Capitol Capsule: FDA's CDER ends 2011 with 30 new drugs and biologics
- Jazz abandons sodium oxybate for fibromyalgia, and may drop intranasal clonazepam
- New Japanese approvals include Xarelto for stroke prevention
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
